Jufe-448 Jun 2026

According to listings on platforms like JavTrailers and JavGuru, the video focuses on a "POV" (point-of-view) experience. The central theme involves the actress interacting directly with the camera from extreme angles, often incorporating:

The "JUFE" prefix identifies the specific label under the studio. Fitch is known for producing high-definition content that targets niche categories such as big tits, lotion-based scenes, and solowork. JUFE-448 - Jav Trailers

| Property | Value / Description | |----------|---------------------| | | 4‑(3‑(tert‑butoxycarbonyl)‑2‑pyridyl)‑2‑phenylquinazolin‑1(3H)-one | | Molecular formula | C₂₈H₂₆N₄O₃ | | Molecular weight | 452.53 g·mol⁻¹ | | LogP (XlogP3-AA) | 3.8 (moderately lipophilic) | | pKa | ≈ 6.5 (basic pyridine nitrogen) | | Solubility | ~12 µM in PBS (pH 7.4), >1 mM in DMSO | | Stability | Stable at −20 °C (dry powder). Degrades slowly in aqueous buffer at pH > 9. | | Stereochemistry | Achiral (no stereocenters) | JUFE-448

To provide the most accurate and useful report, I need a little more information about

The production includes "dirty talk" or verbal stimulation, a standard feature for the "masturbation support" subgenre. Industry Context According to listings on platforms like JavTrailers and

Prepared as a concise, technical overview for scientists, engineers, or industry professionals who may encounter the designation “JUFE‑448” in literature, patents, or product specifications.

| Model | Dosing | Observed Effect | Reference | |-------|--------|----------------|-----------| | | 25 mg kg⁻¹ i.p. QD, 14 days | Tumor volume ↓ 68 % vs. vehicle; 2‑week survival ↑ 45 % | Chen et al., J. Med. Chem. 2023 | | K562 CML cell line | 0.1‑10 µM (in vitro) | EC₅₀ ≈ 0.7 µM for viability loss; apoptosis (caspase‑3 activation) | Li & Zhao, Mol. Cancer Ther. 2024 | | Primary patient‑derived glioblastoma organoids | 0.5 µM (48 h) | Reduced proliferation (Ki‑67 ↓ 55 %); synergistic with temozolomide (CI = 0.73) | Wang et al., Cancer Res. 2024 | JUFE-448 - Jav Trailers | Property | Value

| Target | Assay | IC₅₀ / K D | Selectivity | |--------|-------|----------------------|------------| | | AlphaScreen competition | 48 nM | ≥ 30‑fold vs. BRD2/3 | | BRD4 (bromodomain‑2) | SPR | 62 nM | 20‑fold vs. BRD2/3 | | CREBBP/EP300 bromodomain | FP assay | >10 µM (inactive) | — | | Off‑target kinases (e.g., CDK9, AURKA) | Kinome scan (KINOMEscan®) | >5 µM | — |